Tag Archive for: sarcopenia

Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease

/in

Atrogi’s breakthrough discovery enables chronic use of next-generation, highly selective β2-agonists for the first time in metabolic disease First-in-class oral therapy ATR-258 mimics the effects of exercise – driving fat loss, increasing muscle, and improving metabolism – with broad potential in obesity, diabetes, and age-related muscle loss ATR-258 is set to enter Phase 2 trials […]

Read more

Rejuvenate Biomed’s clinical trial demonstrates the therapeutic potential of RJx-01 in sarcopenia

/in

Cutting-edge therapy shows meaningful improvements in muscle strength, function and fatigue resistance, offering hope for millions suffering from sarcopenia Diepenbeek, Belgium, February 21st, 2024 – Rejuvenate Biomed NV (“Rejuvenate Biomed”), a pioneering clinical-stage platform and pipeline company committed to enhancing lifelong health through innovative therapeutics, today announces breakthrough functional outcome results from its Phase 1b trial […]

Read more

Rejuvenate Biomed announces positive results from Phase 1b clinical trial with RJx-01 in sarcopenia

/in

Diepenbeek, Belgium, October 4, 2023 – Rejuvenate Biomed NV (“Rejuvenate Biomed”), a clinical-stage company dedicated to advancing therapeutics to delay the onset of age-related diseases, today announced the successful completion of a 6-week clinical proof-of-mechanism study with lead candidate RJx-01. RJx-01, a novel combination drug comprising galantamine and metformin, demonstrated positive results in 42 elderly male subjects […]

Read more

Rejuvenate Biomed announces publication of data showing that RJx-01 significantly increases muscle mass, muscle strength and physical performance in sarcopenia mouse models

/in

Sarcopenia – age-related loss of muscle mass and strength – affects up to 1 in 5 elderly people globallyi but there are no approved drugs The newly-published data validate the predictive value of Rejuvenate Biomed’s proprietary drug discovery platforms and have accelerated the advancement of RJx-01 into an ongoing 6-week placebo-controlled trial in human volunteers Diepenbeek, […]

Read more